Oral Medicines to Keep Weight Off After Stopping GLP-1 Treatment in Obesity
Compares orforglipron and phentermine for keeping weight stable in adults with obesity.
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 60 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 31 Jul 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Phentermine Pill
- Orforglipron
- Record updated
- 27 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who lost at least 10% of their body weight on an injectable GLP-1 medicine and live in Massachusetts. It compares orforglipron and phentermine for keeping the weight off.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- History of BMI 30 kg/m² or higher (obesity). Lost at least 10% of body weight since starting an injectable GLP-1 medicine.
- Earlier treatment
- Must be on injectable semaglutide, tirzepatide or a similar GLP-1 medicine now, or have been within the last 8 weeks. Cannot have used other weight loss medicines in the last 3 months.
Main reasons for not taking part
- Current type 2 diabetes
- History of pancreatitis
- Pregnancy, plans to become pregnant, or breastfeeding
- Organ transplant or waiting for one
- Heart disease, heart failure or poorly controlled blood pressure
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Age 18-80 years at screening
- History of BMI ≥30 kg/m²
- Current or recent (within 8 weeks) treatment with injectable semaglutide, tirzepatide, or similar GLP-1 based medication
- Achieved ≥10% body weight loss since initiation of injectable semaglutide, tirzepatide or similar GLP-1 based medication
- Willing to participate in the study after reviewing study infographic and confirming understanding of randomization and study procedures
- Ability to understand and the willingness to sign a written informed consent document
- Residence in Massachusetts
Who cannot take part
- Recent or planned surgical obesity treatment (bariatric surgery >1 year prior to GLP-1 initiation allowed)
- Systemic glucocorticoid therapy >2 weeks within the prior 3 months, or anticipated need within the next 12 months
- Use of medications known to cause significant weight gain (e.g., olanzapine, lithium) within the last 3 months
- Quit using nicotine-containing products less than 6 months prior to baseline visit or intention to quit use in the next year
- Current use strong CYP3A4 inducer medications (which may include: phenytoin, carbamazepine, phenobarbital, primidone, lumacaftor, midostaurin, and pentobarbital)
- Use of prescription or over-the-counter weight loss medications within the last 3 months, other than semaglutide, tirzepatide, or other injectable GLP-1 medication
- Current type 2 diabetes mellitus
- History of pancreatitis
- History of transplanted organ (corneal transplants permitted) or awaiting organ transplant
- Obesity induced by endocrinologic disorders (e.g., Cushing syndrome) or diagnosed monogenic/syndromic obesity (e.g., MC4R deficiency, Prader-Willi syndrome)
- History of significant active or unstable major depressive disorder or other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, serious mood or anxiety disorder) within the past 2 years
- Any history of a suicide attempt
- Acute hepatitis or liver failure/cirrhosis
- Known contraindications to phentermine:; History of coronary artery, cerebrovascular or peripheral arterial disease including myocardial infarction, unstable angina, revascularization, stroke/TIA, carotid intervention, claudication; Poorly-controlled blood pressure (>149/94) or elevated heart rate (>110 bpm); History of cardiac arrhythmia; History of valvular heart disease; Congestive heart failure (any history or current); Active / currently-treated hyperthyroidism (thyroid function screening required if pulse>100); History of glaucoma or been told by an ophthalmologist that you are at high risk for glaucoma; Heavy alcohol use within the last 6 months (men: more than 4 drinks on any day or more than 14 drinks per week; women: more than 3 drinks on any day or more than 7 drinks per week); History of substance use disorder or active use of illicit substances within the last 12 months. Tetrahydrocannabinol (THC)-containing products will not be considered an illicit substance. (e.g., uncontrolled hypertension, active/unstable cardiovascular disease, arrhythmia, hyperthyroidism [thyroid function screening required if pulse>100], glaucoma, history of substance use disorder
- Use of any stimulant medications. 17. Known contraindication to orforglipron (e.g., personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2)
- Any condition (e.g., drug or alcohol abuse, diagnosed eating disorder, other psychiatric disorder) that in the investigator's opinion may preclude protocol compliance
- Chronic kidney disease stage 3b or lower (eGFR <45 mL/min/1.73m²)
- Pregnancy, intent to become pregnant, or current breastfeeding (participants of childbearing potential must have a negative pregnancy test at baseline)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- Massachusetts General HospitalBoston, United StatesContact: Deborah J Wexler, MDNot yet recruiting
About the trial
What the trial wants to find out
This study will compare the effect of orforglipron and phentermine on weight maintenance.
The 2 groups in the trial
- PhentermineExisting treatment, for comparison
Treatment: Phentermine Pill
- OrforglipronExisting treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1-based Therapy Discontinuation
- Plain-language title
- Oral Medicines to Keep Weight Off After Stopping GLP-1 Treatment in ObesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07729332, who can take part
- Record updated
- 27 July 2026